JZP-258 for Narcolepsy
Study Summary
This trial is designed to evaluate the safety and efficacy of XYWAV in participants with narcolepsy who are transitioning from treatment with Xyrem.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: Week 8
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Open-Label Conversion and Treatment Optimization
1 of 1
Experimental Treatment
62 Total Participants · 1 Treatment Group
Primary Treatment: JZP-258 · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 11th, 2021
Last Reviewed: November 28th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Texas | 25.0% |
| Michigan | 25.0% |
| California | 25.0% |
| Other | 25.0% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| WMed Center for Clinical Research | 50.0% |
| Stanford University- Sleep Medicine | 50.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 25.0% |
| Met criteria | 75.0% |
How responsive is this trial?
Typically responds via
| 100.0% | |
Most responsive sites:
- Stanford University- Sleep Medicine: < 48 hours
Average response time
- < 2 Days